Citations

Clear

37 citation(s) found for "Fought, Angela".

Plasma and MRI biomarkers predict post‐mortem tau pathology
Hu, Mingzhao, Przybelski, Scott A. , Fought, Angela J. , Rothberg, Darren M., Reichard, Ross R., Petersen, Ronald C. , Graff‐Radford, Jonathan, Moloney, Christina M. , Algeciras‐Schimnich, Alicia , Nguyen, Aivi T. , Dickson, Dennis W. , Knopman, David S. , Jack, Clifford R. , Mielke, Michelle M. , Graff‐Radford, Jonathan , Murray, Melissa E. , Vemuri, Prashanthi

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S9 | Pages: No page available

10.1002/alz.093893 Get It

AbstractBackgroundImaging and plasma markers are used as key indicators of disease for Alzheimer’s disease (AD) but their usefulness in predicting regional tau pathology is relatively understudied. Our objective was to construct predictive models for regional tau pathology measured on postmortem brain tissue using multiple ante‐mortem AD biomarkers. We focused on hippocampal and parietal regions that were immunostained with AT8 and 2E9 that reflect early and advanced aspects of tangle maturity, respectively.MethodsUsing autopsy data from 63 participants enrolled in the Mayo Clinic Study of Aging (MCSA) where the last clinical visit is within three years of death, we analyzed three ante‐mortem plasma markers ‐ phosphorylated tau protein at the threonine 181 residue, glial fibrillary acidic protein, total ß‐amyloid Aß42 relative to Aß40 ratio (Quanterix Simoa HD‐X Analyzer), and three regional MRI markers computed using SPM12 ‐ parietal thickness, parietal volume relative to total intracranial volume ratio, and hippocampal volume adjusted for total intracranial volume. Based on eight separate cross‐sectional linear regression models weighted by the inverse of time from last visit to death, we estimated the multiple and partial R2 predicting post‐mortem pathology measures, including AT8 and 2E9 in both the hippocampal and parietal regions. All models were adjusted for age, sex, and cardiovascular and metabolic conditions score.ResultsThe MRI models (R2 of 0.26‐0.53) had greater predictive power compared to the plasma models (R2 of 0.17‐0.26). The best multiple R2 was 0.53 for prediction of hippocampal AT8 using antemortem hippocampal volume adjusted for total intracranial volume followed by R2 of 0.43 for prediction of hippocampal 2E9 using hippocampal volume adjusted for total intracranial volume. Though the model prediction of parietal AT8 and 2E9 measurements was low (R2 of 0.21‐0.26), parietal thickness exhibited better predictive performance than parietal volume relative to total intracranial volume ratio.ConclusionsThe data we presented here may be utilized to validate biomarkers using regional pathology. Our results support that regional MRI is sensitive to tau pathology. Newer MRI methods should be tested to examine the specificity of newer quantitative measurements to tau pathology.
A Comparison of DTI‐Based Measures as Predictors of Future Cerebrovascular Degeneration
Przybelski, Scott A. , Lesnick, Timothy G. , Fought, Angela J. , Raghavan, Sheelakumari , Kamykowski, Michael G. , Graff‐Radford, Jonathan, Knopman, David S. , Petersen, Ronald C., Reid, Robert I. , Graff‐Radford, Jonathan , Knopman, David S. , Petersen, Ronald C. , Jack, Clifford R. , Vemuri, Prashanthi

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S9 | Pages: No page available

10.1002/alz.093860 Get It

AbstractBackgroundThere has been a recent proliferation of various quantities based on single shell Diffusion Tensor Imaging (DTI) for capturing overall cerebrovascular health, especially Small Vessel Disease (SVD) as a single number. The existing literature has gaps in the comparison of these measures, so we evaluated them as predictors of both current and future White Matter Hyperintensity (WMH) as a proxy of SVD.MethodUsing baseline 3T MRI examinations (T1, DTI, FLAIR scans) of 598 participants (>60 years, amyloid negative, to limit to those on the SVD pathway) from the Mayo Clinic Study of Aging, we calculated five summary DTI quantities with varying degree of complexity. We estimated their partial R2 from cross‐sectional linear regression models and computed semi‐partial R2 from mixed models predicting WMH volume as a percentage of Total Intracranial Volume (TIV). All models were adjusted for age, sex, and scanner model, and the WMH and based were log‐transformed before fitting. We also conducted subset analyses with high (WMH+) vs. low (WMH‐) baseline WMH load (cut at 1.62%) to compare the performance of the measures in early vs. widespread WMH.ResultAll MD‐based quantities computed on the whole brain, including FWF, performed similarly to each other, but Genu FA underperformed at explaining WMH variance (Table 1). PSMD (skeletonized or atlas based) was more sensitive in WMH+ but dramatically less so in WMH‐. In WMH‐ and overall cohort, FWF and JHU MD (which is a simple averaging of MD in the JHU atlas) performed well.ConclusionAll MD‐based measures performed similarly to each other in the whole dataset but dichotomizing by WMH load showed interesting differences. PSMD measurements are driven by the extreme end (95th percentile) of the MD distribution and therefore more sensitive in WMH+. Genu FA, a regional measure, was not useful for predicting whole brain WMH change. We noticed some variation in how the quantities are affected by scanner model (GE Signa HDxt and Discovery 750) which needs broader investigation. Simply averaging MD over WM avoids additional processing and is more sensitive to WM degeneration that is not (yet) severe.
Associations of blood pressure with white matter hyperintensities later in life; influence of short-term menopausal hormone therapy
Kara, Firat , Tosakulwong, Nirubol , Lesnick, Timothy G. , Fought, Angela J. , Kendell-Thomas, June, Kapoor, Ekta , Faubion, Laura L. , Fields, Julie A. , Min, Hoon‐Ki , Lowe, Val J. , Jack, Clifford R. , Bailey, Kent R. , James, Taryn T. , Løbo, Rogerio A. , Pal, Lubna, Hammers, Dustin B. , Cedars, Marcelle I. , Miller, Virginia M. , Harman, S. Mitchell , Gleason, Carey E. , Kantarci, Kejal , Pal, Lubna , Kantarci, Kejal , Min, Hoon-Ki Paul , Jack, Clifford R , Kara, Firat , Kapoor, Ekta , Schwarz, Christopher G. , Senjem, Matthew L. , Manson, JoAnn E. , Hammers, Dustin B , Malek‐Ahmadi, Michael , Naftolin, Frederick , Santoro, Nanette F. , Dowling, N. Maritza

Mayo Clinic

Menopause | December 27, 2024 | Volume: 32 | Issue: 1 | Pages: 12-22

10.1097/gme.0000000000002481 | PMID 39729067 Get It

Abstract Objective To assess the association of systolic and diastolic blood pressure (SBP and DBP) in recently menopausal women with white matter hyperintensity (WMH) volume later in life and determine whether short-term menopausal hormone therapy (mHT) modifies these associations. Methods Kronos Early Estrogen Prevention Study (KEEPS) was a multicenter, randomized, double-blinded, placebo-controlled 4-year mHT trial (oral conjugated equine estrogens or transdermal 17β-estradiol). KEEPS continuation was an observational follow-up of the participants 10 years after the end of mHT. The associations between KEEPS baseline blood pressure (BP) with KEEPS continuation WMH volume were examined adjusting for covariates in model 1 (age, total intracranial volume, study site, mHT type) and model 2 (additionally conventional CVD risk factors). Interaction terms (BP × mHT type) were added into the linear regression models. Results The mean ± SD ages of participants were 53 (±2) years at KEEPS baseline and 67 (±2) years at KEEPS continuation. Elevated BP at KEEPS baseline was associated with greater WMH volume measured 14 years later (model 1: SBP: β = 0.01 [95% CI, 0.001‐0.01] and DBP: β = 0.01 [95% CI, 0.003‐0.03]) and after additionally adjusting for CVD risk factors (model 2). We did not find any evidence that mHT versus placebo modified these associations. Topographically, higher BP was associated with greater periventricular WMH in the frontal and parietal lobes. Conclusion Our findings suggest the importance of maintaining normal BP in recently postmenopausal women with low CVD risk, irrespective of short-term mHT usage, to potentially reduce the risk of WMH later in life.
Transcytosis as a Mechanism of HIV-1 Entry into Columnar Epithelial Explants of the Female Reproductive Tract
Anderson, Meegan R. , McRaven, Michael D. , Allen, E.J. , Fought, Angela J. , Hope, Thomas J. , Hope, Thomas J , Carias, Ann M. , Allen, Edward

Mayo Clinic

AIDS Research and Human Retroviruses | December 12, 2024 | Volume: 41 | Issue: 3 | Pages: 167-173

10.1089/aid.2024.0045 | PMID 39665594 Get It

Intraoperative Radiation Therapy for Recurrent Cervical and Endometrial Cancer: Predicting Morbidity and Mortality in a Contemporary Cohort
Howlett, Lindsay N. , Fadadu, Priyal , Grcevich, Leah, Fought, Angela J. , McGree, Michaela E. , Giannini, Andrea , Butler, Kristina , Marnholtz, Amanda A., Haddock, Michael G. , Garda, Allison E. , Dowdy, Sean C. , Kumar, Amanika , Fadadu, Priyal P , Grcevich, Leah O, Butler, Kristina A., Garda, Allison E , Kumar, Amanika , Tortorella, Lucia , Langstraat, Carrie

Mayo Clinic

Cancers | October 28, 2024 | Volume: 16 | Issue: 21 | Pages: 3628

10.3390/cancers16213628 | PMID 39518067 Get It

Background/Objectives: Our objective was to describe the use of intraoperative radiation therapy (IORT) for the treatment of recurrent/persistent cervical or endometrial cancer and assess predictors of postoperative complications and 3-year mortality. Methods: In this multi-site retrospective study, data were abstracted for recurrent/persistent endometrial or cervical cancer patients who underwent IORT from June 2004 to May 2021. Complications were graded on the six-point Accordion scale. Variables associated with complications were analyzed with univariate logistic regression, while variables associated with death within 3 years were analyzed with Cox proportional hazards modeling. Survival was analyzed with the Kaplan–Meier method. Results: Eighty patients had planned IORT for recurrent/persistent endometrial (n = 35) or cervical cancer (n = 45). The mean age of the cohort was 56.8 years (SD = 13.7), and the median disease-free interval from primary disease to recurrence was 20.0 months (IQR 10.0–63.1). The overall survival at 3 years was 48.6% (95% CI: 38.3–61.6%) with a median survival of 2.8 years. Within 30 days postoperative, 16 patients (20.1%) had grade 3–5 complications and one death (1.3%) occurred. Factors associated with grade 3+ complication included ECOG PS 2–3 (OR 18.00, p = 0.04), neoadjuvant chemotherapy and/or immunotherapy (OR 6.98, p < 0.01), and pelvic sidewall involvement (OR 8.80, p = 0.04). Factors associated with death within 3 years of surgery included ECOG PS 2–3 (HR 8.97, p < 0.01), neoadjuvant chemotherapy and/or immunotherapy (HR 2.34, p = 0.03), whether exenteration was performed (HR 2.64, p = 0.01), and positive resection margin (HR 3.37, p < 0.01). Conclusions: In well-selected patients, IORT is a feasible and safe option for the treatment of recurrent/persistent gynecologic malignancy with an appreciable survival benefit.
The Quality of Life after Endometrial Cancer Study: Baseline Characteristics and Patient-Reported Outcomes
Warring, Simrit K. , Yost, Kathleen J. , Dowdy, S.C., Kumar, Amanika , Lemens, Maureen A. , Oort, Chelsie C. Van, Fought, Angela J. , Gree, Michaela E. Mc, Glaser, Gretchen , Warring, Simrit, Kumar, Amanika , Lemens, Maureen A , Van Oort, Chelsie C, Mc Gree, Michaela E, Glaser, Gretchen , Cheville, Andrea , Faubion, Stephanie S. , Mariani, Andrea

Mayo Clinic

Current Oncology | September 19, 2024 | Volume: 31 | Issue: 9 | Pages: 5557-5572

10.3390/curroncol31090412 | PMID 39330040 Get It

Endometrial cancer (EC) patients make up the second largest group of female cancer survivors. Patient-reported outcomes (PROs) including quality of life (QOL) and sexual function and satisfaction (SF and S) are critical facets of survivorship. This prospective, longitudinal study assesses associations between baseline characteristics and PROs after treatment. Herein, we report the baseline clinical characteristics and PROs prior to treatment initiation. Outcomes post-treatment over time will be reported separately. Patients with planned surgery for EC were prospectively enrolled in 2019–2021 and administered the European Organization for Research and Treatment of Cancer (EORTC) QOL Questionnaire Core 30 (QLQ-C30), EORTC QLQ EC Module (EN24), Patient-Reported Outcomes Measurement Information System (PROMIS), and the Mayo Clinic lower extremity lymphedema (LEL) questionnaire. This study enrolled 198 patients with a mean (SD) age of 63.6 (9.8) years and body mass index of 35.5 (8.3) kg/m2. No significant differences in the PROs for the QOL were seen when compared to the reference means (SD) except for the lower interest in sexual activity (31.9 (9.8) vs. 47.5 (SE0.70)) and lower fatigue (21.3 (19.8) vs. 31.7 (25.9)). Increased obesity was associated with an increased likelihood of LEL (p < 0.01) and multiple QOL scales, including poorer global health status (p < 0.01) and physical functioning (p < 0.01). Prior to treatment initiation for EC, the patients had a similar QOL compared to that of the general population. The patients with increasing obesity, a known risk factor for EC, had worse overall global health status and physical functioning. A better understanding of these QOL measures is imperative for earlier identification and intervention of patients at risk of chronic impairments from EC treatment.
White Matter Abnormalities Track Disease Progression in Multiple System Atrophy
Raghavan, Sheelakumari , Lesnick, Timothy G. , Fought, Angela J. , Thostenson, Kaely, Sparrman, Kohl L. Johnson, Gehrking, Tonette L., Gehrking, Jade A., Sletten, David M., Low, Phillip A. , Thostenson, Kaely B, Johnson Sparrman, Kohl L, Singer, Wolfgang , Vemuri, Prashanthi , Castillo, Anna , Reid, Robert I. , Vemuri, Prashanthi

Mayo Clinic

Movement Disorders Clinical Practice | June 24, 2024 | Volume: 11 | Issue: 9 | Pages: 1085-1094

10.1002/mdc3.14147 | PMID 38923361 Get It

Abstract Background White matter (WM) abnormalities have been implicated in clinically relevant functional decline in multiple system atrophy (MSA). Objective To identify the WM and gray matter (GM) abnormalities in MSA and assess the utility of longitudinal structural and diffusion changes as surrogate markers for tracking disease progression in MSA. Methods Twenty‐seven participants with early MSA [15 with clinically predominant cerebellar (MSA‐C) and 12 with clinically predominant parkinsonian features (MSA‐P)] and 14 controls were enrolled as a part of our prospective, longitudinal study of synucleinopathies. Using structural magnetic resonance imaging (MRI) and diffusion MRI (diffusion tensor and neurite orientation and dispersion density imaging), we analyzed whole and regional brain changes in these participants. We also evaluated temporal imaging trajectories based on up to three annual follow‐up scans and assessed the impact of baseline diagnosis on these imaging biomarkers using mixed‐effect models. Results MSA patients exhibited more widespread WM changes than GM, particularly in the cerebellum and brainstem, with greater severity in MSA‐C. Structural and diffusion measures in the cerebellum WM and brainstem deteriorated with disease progression. Rates of progression of these abnormalities were similar in both MSA subtypes, reflecting increasing overlap of clinical features over time. Conclusion WM abnormalities are core features of MSA disease progression and advance at similar rates in clinical MSA subtypes. Multimodal MRI imaging reveals novel insights into the distribution and pattern of brain abnormalities and their progression in MSA. Selected structural and diffusion measures may be useful for tracking disease progression in MSA clinical trials.
Differences in physical and emotional distress amongst patients undergoing neoadjuvant chemotherapy versus surgery for advanced ovarian cancer: Patient-reported outcomes at diagnosis.
Mokshagundam, Shilpa , McGree, Michaela E. , Fought, Angela J. , Ishitani, Karen P, Lee, Minji K. , Kumar, Amanika

Mayo Clinic

Journal of Clinical Oncology | June 6, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 5546-5546

10.1200/jco.2024.42.16_suppl.5546 Get It

5546 Background: Advanced ovarian cancer (OC) is managed with cytoreductive surgery and platinum-based chemotherapy. Prehabilitation is a multimodal intervention to improve physical and mental health prior to oncologic surgery. This study evaluates baseline differences in clinical characteristics, functional status, and patient-reported outcomes (PROs) between patients undergoing primary cytoreductive surgery (PCS) versus neoadjuvant chemotherapy (NACT) who enrolled in a prospective prehabilitation trial. Methods: This was a single-institution, non-randomized prospective behavioral intervention trial of patients with suspected advanced stage (IIIC/IV) OC. Baseline functional testing included the Short Physical Performance Battery (SPPB), Fried Frailty Index (FFI), gait speed, and grip strength. Patient-Reported Outcomes Measurement Information System (PROMIS) metrics, the Mindfulness Attention Awareness Scale (MAAS), and the Perceived Stress Scale (PSS-10) were used to evaluate PROs. Comparisons between cohorts utilized two-sample t-test or Kruskal Wallis test for continuous variables and chi-square or Fisher’s exact test for categorical variables. T-scores were obtained for PROMIS data using the HealthMeasures Scoring Service; validated cut points for PROMIS, MAAS, and PSS-10 were used for categorization. Results: Amongst the 53 enrolled patients, physical and emotional distress was higher amongst OC patients compared to population means. When compared to PCS patients, NACT patients were more likely to report “severe” in at least one PROMIS domain (emotional distress and anxiety, pain interference, physical function, and fatigue, p<0.01). NACT patients reported significantly higher levels of perceived stress (p<0.01). NACT patients were more likely to have stage IV disease, albumin <3.5 g/dL, and lower gait speed and grip strength (all p<0.01). Despite differences in clinical variables and PROs including physical function, there were no measurable differences in physical function based on SPPB and FFI. Conclusions: Advanced OC patients have high psychosocial needs, with NACT patients reporting severe perceived symptoms on PRO measures. The PSS-10 may be a valuable screening tool for patients undergoing NACT to prioritize supportive care services. Clinical trial information: NCT05047926 . [Table: see text]
0759 Insomnia with Reduced Sleep Is a Risk Factor for Global Cognitive Decline in Cognitively Unimpaired Older Adults
Fought, Angela J. , Przybelski, Scott A. , Petersen, Ronald C. , Graff‐Radford, Jonathan , Carvalho, Diego Z. , Kolla, Bhanu Prakash , Louis, Erik K. St. , McCarter, Stuart J. , Machulda, Mary M. , Boeve, Bradley F. , Jack, Clifford R. , Vemuri, Prashanthi

Mayo Clinic

SLEEP | April 20, 2024 | Volume: 47 | Issue: Supplement_1 | Pages: A325-A326

10.1093/sleep/zsae067.0759 Get It

Abstract Introduction Meta-analytic studies support that insomnia is a risk factor for cognitive decline and dementia, but limited accounting of confounders reduces their validity. Further, it is unclear whether these associations are driven by specific insomnia phenotypes. In this study, we aimed to assess the relationship between insomnia and longitudinal global cognitive decline in community-dwelling older adults after considering self-reported sleep duration changes and other important characteristics. Methods From the Mayo Clinic Study of Aging (MCSA) cohort, we identified all (age&gt;=50yo) cognitively unimpaired participants at baseline without comorbid neurological disease with at least two previous comprehensive neuropsychological evaluations. Participants with at least two occurrences of insomnia ICD diagnosis (by EMR and Rochester Epidemiological Project data) at least 30 days apart were classified as having insomnia, and those without any instance of diagnosis were considered negative for insomnia. Changes in sleep duration were assessed using the question #16 of BDI-2 and categorized in reduced sleep (yes/no). We fit mixed-effect regression models to assess whether insomnia was associated with standardized global cognitive scores, after adjusting for age, sex, education, APOEe4, composite cardiovascular and metabolic conditions scores, anxiety/depression, reduced sleep, OSA (ICD diagnosis), alcoholism (CAGE≥2), and pain (NSAIDs use). Number of cognitive assessments and time from baseline were included as both fixed and random effects. Multiple interactions (e.g. insomnia*reduced sleep) were included. A backward stepwise procedure maintaining the hierarchical principal for interactions was utilized to reach the most parsimonious models. Results 3063 participants (50.24% males, aged 70±9.73 at baseline) were included. Insomnia alone was not associated with a decrease in global cognition, but when combined with subjective reduction in sleep duration at baseline it was associated with a -0.19 (95% CI: -0.32, -0.07; interaction p=0.01) reduction in global cognitive scores. This was equivalent to approximately 3 additional years of age or 6 cardiometabolic comorbidities at baseline. The effect size was greater than those associated with baseline cognition for having any APOE e4 allele (-0.12) and alcoholism (-0.15). Conclusion Insomnia with reduced sleep duration phenotype is a potentially modifiable risk factor for cognitive decline in older adults. Further studies with objective sleep measures are necessary for objective confirmation. Support (if any) NIA/NIH
Mapping White Matter Changes to Monitor Disease Progression in Multiple System Atrophy (P5-3.008)
Raghavan, Sheela Kumari, Lesnick, Timothy G. , Fought, Angela J. , Thostenson, Kaely, Kohl, J., Gehrking, Tonette L., Gehrking, Jade A., Sletten, David M., Low, Philip, Castillo, Anna , Reid, Robert I. , Kohl, Johnson Sparrman, Singer, Wolfgang , Vemuri, Prashanthi

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000206227 Get It